000098334 001__ 98334
000098334 005__ 20210126163933.0
000098334 0248_ $$2sideral$$a122077
000098334 037__ $$aART-2019-122077
000098334 041__ $$aeng
000098334 100__ $$0(orcid)0000-0001-8762-5457$$aSancho-Albero, M.$$uUniversidad de Zaragoza
000098334 245__ $$aCancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis
000098334 260__ $$c2019
000098334 5060_ $$aAccess copy available to the general public$$fUnrestricted
000098334 5203_ $$aP151
The transformational impact of bioorthogonal chemistries has inspired new strategies for the in vivo synthesis of bioactive agents through non-natural means. Among these, Palladium (Pd) catalysts have played a prominent role in the growing subfield of bioorthogonal catalysis by producing xenobiotics and uncaging biomolecules in living systems, and new exciting Pdcatalyzed reactions and applications continue to emerge. However, delivering catalysts selectively to specific cell types still lags behind catalyst development. Towards this goal, we have developed a bio-artificial device consisting of cancer-derived exosomes loaded with Pd catalysts by a novelmethod that enables the controlled assembly of Pd nanosheets directly inside the vesicles. This new hybrid system mediates Pdtriggered dealkylation reactions in vitro and inside cells and displays preferential tropism for their progenitor cells. The use of Trojan exosomes to deliver abiotic catalysts into designated cancer cells creates the opportunity for a new targeted therapy modality: exosome-directed catalyst prodrug therapy, whose first steps are presented herein with the cell-specific release of the recently approved anticancer drug panobinostat.
000098334 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000098334 590__ $$a4.273$$b2019
000098334 591__ $$aBIOTECHNOLOGY & APPLIED MICROBIOLOGY$$b30 / 156 = 0.192$$c2019$$dQ1$$eT1
000098334 591__ $$aGENETICS & HEREDITY$$b38 / 177 = 0.215$$c2019$$dQ1$$eT1
000098334 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b40 / 138 = 0.29$$c2019$$dQ2$$eT1
000098334 592__ $$a1.648$$b2019
000098334 593__ $$aGenetics$$c2019$$dQ1
000098334 593__ $$aMolecular Medicine$$c2019$$dQ1
000098334 593__ $$aMolecular Biology$$c2019$$dQ2
000098334 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000098334 700__ $$aRubio-Ruiz, B.
000098334 700__ $$aPerez-Lopez, A.M.
000098334 700__ $$0(orcid)0000-0002-6873-5244$$aSebastian, V.$$uUniversidad de Zaragoza
000098334 700__ $$0(orcid)0000-0003-4160-9720$$aMartin-Duque, P.
000098334 700__ $$0(orcid)0000-0003-3165-0156$$aArruebo, M.$$uUniversidad de Zaragoza
000098334 700__ $$aUnciti-Broceta, A.
000098334 700__ $$0(orcid)0000-0002-8701-9745$$aSantamaria, J.$$uUniversidad de Zaragoza
000098334 7102_ $$15005$$2555$$aUniversidad de Zaragoza$$bDpto. Ing.Quím.Tecnol.Med.Amb.$$cÁrea Ingeniería Química
000098334 773__ $$g30, 11 (2019), A63-A64$$pHum. gene ther.$$tHUMAN GENE THERAPY$$x1043-0342
000098334 85641 $$uhttps://www.liebertpub.com/doi/pdf/10.1089/hum.2019.29095.abstracts$$zTexto completo de la revista
000098334 8564_ $$s72064$$uhttps://zaguan.unizar.es/record/98334/files/texto_completo.pdf$$yVersión publicada
000098334 8564_ $$s3431252$$uhttps://zaguan.unizar.es/record/98334/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000098334 909CO $$ooai:zaguan.unizar.es:98334$$particulos$$pdriver
000098334 951__ $$a2021-01-26-15:09:08
000098334 980__ $$aARTICLE